Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A- rearranged acute myeloid leukemia

Blood (2024) 144 (24): 2554–2557.

https://doi.org/10.1182/blood.2024026605

Published: 2024

Includes: Supplemental data

Journal Articles

Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission

Ing Soo Tiong, Satwica Yerneni, Tamia Nguyen, Adam Ivey, Natasha S. Anstee, Emma Palfreyman, Ashish Bajel, Emad Uddin Abro, Devendra Hiwase, Andrew H Wei, Piers Blombery

Blood (2024) 144 (Supplement 1): 51.

https://doi.org/10.1182/blood-2024-201145

Published: 2024

Journal Articles

DNA Damage Repair Pathway Variants Are Frequent in Patients Undergoing CAR-T Cell Therapy for Lymphoma and Associated with Increased Risk of Myeloid Neoplasia Post Cytotoxic Therapy

Zhi Han Yeoh, Ing Soo Tiong, Mark R Dowling, Hamish W Scott, Nicole O'Leary, Samantha van der Linde, Tamia Nguyen, Simon J Harrison, Ashish Bajel, Andrew H Wei, Piers Blombery

Blood (2024) 144 (Supplement 1): 653.

https://doi.org/10.1182/blood-2024-204494

Published: 2024

Journal Articles

Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A- rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial

Blood (2024) 144 (Supplement 1): 223.

https://doi.org/10.1182/blood-2024-202895

Published: 2024

Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Blood (2023) 142 (23): 1960–1971.

https://doi.org/10.1182/blood.2023020301

Published: 2023

Includes: Supplemental data

Journal Articles

Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations

Blood (2023) 142 (Supplement 1): 423.

https://doi.org/10.1182/blood-2023-185321

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

Blood (2023) 142 (Supplement 1): 193.

https://doi.org/10.1182/blood-2023-178596

Published: 2023

Journal Articles

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Ing Soo Tiong, Tamia Nguyen, Charis Teh, Chong Chyn Chua, Sarah Ftouni, Thomas E Lew, Fiona C. Brown, Donia Moujalled, Christine Muttiah, Daniel Gray, Mary Ann Anderson, Philip A. Thompson, Constantine S. Tam, John F. Seymour, Sarah-Jane Dawson, Andrew H. Wei, Geoffrey Lindeman, Piers Blombery

Blood (2023) 142 (Supplement 1): 2688.

https://doi.org/10.1182/blood-2023-180386

Published: 2023

Journal Articles

Pre-Transplant Measurable Residual Disease (MRD) Detection of KMT2A- rearranged Acute Myeloid Leukemia Is Strongly Associated with Inferior Post-Transplant Outcome

Sun Loo, Nicola Potter, Adam Ivey, Jenny O'Nions, Roderick Moon, Chun Yew Fong, Natasha Anstee, Ing Soo Tiong, Chong Chyn Chua, Jad Othman, Hannah Renshaw, Robert Baker, Nigel H. Russell, Ashish Bajel, Hsin-An Hou, Richard Dillon, Andrew H. Wei

Blood (2023) 142 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2023-185541

Published: 2023

Journal Articles

Pretransplant FLT3 -ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Blood (2022) 140 (22): 2407–2411.

https://doi.org/10.1182/blood.2022016567

Published: 2022

Includes: Supplemental data

Journal Articles

Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy

Mithun V. Shah, Rakchha Chhetri, Ruchita Dholakia, Hassan B. Alkhateeb, Aref Al-Kali, Mrinal M. Patnaik, Naseema Gangat, Andrew H. Wei, Ing Soo Tiong, Kebede H. Begna, Devendra Hiwase

Blood (2021) 138 (Supplement 1): 36.

https://doi.org/10.1182/blood-2021-147049

Published: 2021

Journal Articles

Mutational and Copy Number Profiling of Circulating Tumor DNA in Acute Myeloid Leukemia Using Targeted Next Generation Sequencing

Ing Soo Tiong, MBBS,FRACP,FRCPA, Clarissa Wilson, BSc,MSc, Satwica Yerneni, MS, John Markham, Karen Dun, BSc,FHGSA, Ashish Bajel, FRACP, Ella R Thompson, PhD BSc, David Alan Westerman, MBBS, FRCPA, FRACP, Piers Blombery, MBBS

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-138933

Published: 2020

Journal Articles

The Natural History of NPM1 MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML)

Ing Soo Tiong, MBBS,FRACP,FRCPA, Richard Dillon, MA, PhD MRCP, FRCPath, Adam Ivey, BSc, MSc, PhD, Chung Hoow Kok, BSc, PhD, James Anton Kuzich, MBBS, Nisha Thiagarajah, MBBS, Ashish Bajel, FRACP, Nicola Potter, PhD, Matthew Smith, MBBS, Claire Hemmaway, Abin Thomas, Amanda Gilkes, Nigel H. Russell, MD, Andrew H. Wei

Blood (2020) 136 (Supplement 1): 25–27.

https://doi.org/10.1182/blood-2020-140296

Published: 2020

Journal Articles

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Blood (2020) 136 (Supplement 1): 36–38.

https://doi.org/10.1182/blood-2020-137334

Published: 2020

Journal Articles

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

Chong Chyn Chua, MBBS, John Reynolds, PhD, Jessica M Salmon, PhD, Chun Fong, Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Ing Soo Tiong, MBBS,FRACP,FRCPA, Shaun Fleming, MBBS,, Sarah MacRaild, Donia M Moujalled, PhD, Giovanna Pomilio, Nik Cummings, Julie McManus, Adam Ivey, BSc, MSc, PhD, Purvi M Kakadia, PhD, Stefan K. Bohlander, MD, Andrew W. Roberts, MBBS, PhD FRACP, FRCPA, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 462.

https://doi.org/10.1182/blood-2019-126640

Published: 2019

Journal Articles

Hypermethylation of GADD45A Defines a Methylation Profile Distinct to Mutant IDH1/2 , and Correlates with More Aggressive AML

Blood (2016) 128 (22): 2877.

https://doi.org/10.1182/blood.V128.22.2877.2877

Published: 2016

Journal Articles

Metabolic Profiling of Adult Acute Myeloid Leukemia (AML)

Blood (2016) 128 (22): 1684.

https://doi.org/10.1182/blood.V128.22.1684.1684

Published: 2016

Journal Articles

The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation

Michelle Perugini, PhD, Saumya E Samaraweera, PhD, Anna L Brown, PhD, Nik Cummings, BSc, Silke Danner, Ing Soo Tiong, MBChB, Francine E Garrett-Bakelman, MD PhD, Martin P. Carroll, MD, Michael W. Becker, MD, Stephen S. Chung, MD, Christopher Y. Park, MD PhD, Christopher E Mason, PhD, Monica L. Guzman, PhD, Ross L. Levine, MD, Ari M Melnick, MD, Luen Bik To, MBBS, PhD, Andrew H Wei, MBBS, PhD, Ian D Lewis, MBBS, PhD, Richard J D'Andrea, PhD

Blood (2014) 124 (21): 69.

https://doi.org/10.1182/blood.V124.21.69.69

Published: 2014

Journal Articles

Whole Exome Sequencing of Acute Myeloid Leukaemia Patients Identifies Somatic and Germline Mutations in Fanconi Anaemia Genes

Kyaw Zeya Maung, BSc, James X Gray, MD PhD, Paul J Leo, PhD, Mahmoud Bassal, BSc, Anna L Brown, PhD, Sarah C Bray, PhD, Ing Soo Tiong, MBChB, Chung H Kok, PhD, Andrew Deans, PhD, Mhairi Marshall, PhD, Brooke Gardiner, PhD, Evgeny A Glazov, PhD, Paula Marlton, MBBS, Devinder Gill, MD, Luen Bik To, MBBS, PhD, Ian D Lewis, MBBS, PhD, Richard J D'Andrea, PhD, Thomas J Gonda, PhD

Blood (2014) 124 (21): 698.

https://doi.org/10.1182/blood.V124.21.698.698

Published: 2014

NARROW

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A- rearranged acute myeloid leukemia

Venetoclax-Based Measurable Residual Disease Directed Therapy in Acute Myeloid Leukemia Is Associated with Emergent TP53 Microclones in Remission

DNA Damage Repair Pathway Variants Are Frequent in Patients Undergoing CAR-T Cell Therapy for Lymphoma and Associated with Increased Risk of Myeloid Neoplasia Post Cytotoxic Therapy

Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A- rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Pre-Transplant Measurable Residual Disease (MRD) Detection of KMT2A- rearranged Acute Myeloid Leukemia Is Strongly Associated with Inferior Post-Transplant Outcome

Pretransplant FLT3 -ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy

Mutational and Copy Number Profiling of Circulating Tumor DNA in Acute Myeloid Leukemia Using Targeted Next Generation Sequencing

The Natural History of NPM1 MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML)

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

Hypermethylation of GADD45A Defines a Methylation Profile Distinct to Mutant IDH1/2 , and Correlates with More Aggressive AML

Metabolic Profiling of Adult Acute Myeloid Leukemia (AML)

The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation

Whole Exome Sequencing of Acute Myeloid Leukaemia Patients Identifies Somatic and Germline Mutations in Fanconi Anaemia Genes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only